DE60007360T2 - Amorphe modifikation von torasemid - Google Patents

Amorphe modifikation von torasemid Download PDF

Info

Publication number
DE60007360T2
DE60007360T2 DE60007360T DE60007360T DE60007360T2 DE 60007360 T2 DE60007360 T2 DE 60007360T2 DE 60007360 T DE60007360 T DE 60007360T DE 60007360 T DE60007360 T DE 60007360T DE 60007360 T2 DE60007360 T2 DE 60007360T2
Authority
DE
Germany
Prior art keywords
torasemid
amorphe
modification
amorphe modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60007360T
Other languages
English (en)
Other versions
DE60007360D1 (de
Inventor
Darko Filic
Miljenko Dumic
Bozena Klepic
Aleksandar Danilovski
Marijan Tudja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Farmaceutika dd
Original Assignee
Pliva Farmaceutika dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Farmaceutika dd filed Critical Pliva Farmaceutika dd
Publication of DE60007360D1 publication Critical patent/DE60007360D1/de
Application granted granted Critical
Publication of DE60007360T2 publication Critical patent/DE60007360T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
DE60007360T 2000-03-20 2000-05-02 Amorphe modifikation von torasemid Expired - Fee Related DE60007360T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR20000162A HRP20000162B1 (en) 2000-03-20 2000-03-20 Amorphous torasemide modification
PCT/HR2000/000011 WO2001070694A1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification

Publications (2)

Publication Number Publication Date
DE60007360D1 DE60007360D1 (de) 2004-01-29
DE60007360T2 true DE60007360T2 (de) 2004-10-07

Family

ID=10947070

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60007360T Expired - Fee Related DE60007360T2 (de) 2000-03-20 2000-05-02 Amorphe modifikation von torasemid

Country Status (29)

Country Link
US (1) US6767917B1 (de)
EP (1) EP1272470B1 (de)
JP (1) JP2003528083A (de)
KR (1) KR20020093847A (de)
CN (1) CN1211368C (de)
AR (1) AR023788A1 (de)
AT (1) ATE256662T1 (de)
AU (1) AU2000241348A1 (de)
BG (1) BG107208A (de)
BR (1) BR0017175A (de)
CA (1) CA2401908A1 (de)
CZ (1) CZ20023436A3 (de)
DE (1) DE60007360T2 (de)
EA (1) EA004950B1 (de)
EE (1) EE200200534A (de)
ES (1) ES2213006T3 (de)
GE (1) GEP20043300B (de)
HR (1) HRP20000162B1 (de)
HU (1) HUP0300596A3 (de)
IL (1) IL151801A0 (de)
IS (1) IS6551A (de)
MX (1) MXPA02009210A (de)
NO (1) NO20024464L (de)
PL (1) PL357154A1 (de)
PT (1) PT1272470E (de)
SK (1) SK15092002A3 (de)
WO (1) WO2001070694A1 (de)
YU (1) YU70502A (de)
ZA (1) ZA200208309B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200200353T2 (tr) * 1999-08-11 2002-06-21 Teva Pharmaceutical Industries Ltd. Torsemid Polimorfları
IN192178B (de) * 2001-08-03 2004-03-06 Ranbaxy Lab
AU2004270161A1 (en) 2003-08-28 2005-03-17 Nicox S.A. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2006091716A2 (en) 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
US6096779A (en) 1995-02-22 2000-08-01 Hoechst Pharmaceuticals & Chemicals K.K. Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
IN182496B (de) 1996-02-20 1999-04-17 Reddy Research Foundation
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
TR200200353T2 (tr) 1999-08-11 2002-06-21 Teva Pharmaceutical Industries Ltd. Torsemid Polimorfları

Also Published As

Publication number Publication date
PL357154A1 (en) 2004-07-12
HRP20000162A2 (en) 2001-12-31
JP2003528083A (ja) 2003-09-24
EA004950B1 (ru) 2004-10-28
BR0017175A (pt) 2002-12-10
CZ20023436A3 (cs) 2003-03-12
MXPA02009210A (es) 2004-09-06
DE60007360D1 (de) 2004-01-29
WO2001070694A8 (en) 2002-03-21
EE200200534A (et) 2004-04-15
ATE256662T1 (de) 2004-01-15
HUP0300596A3 (en) 2005-08-29
CN1452613A (zh) 2003-10-29
AU2000241348A1 (en) 2001-10-03
ES2213006T3 (es) 2004-08-16
KR20020093847A (ko) 2002-12-16
CN1211368C (zh) 2005-07-20
NO20024464L (no) 2002-09-20
HUP0300596A2 (hu) 2003-07-28
WO2001070694A1 (en) 2001-09-27
BG107208A (en) 2003-07-31
YU70502A (sh) 2006-01-16
NO20024464D0 (no) 2002-09-18
IL151801A0 (en) 2003-04-10
SK15092002A3 (sk) 2003-05-02
EP1272470B1 (de) 2003-12-17
EA200201003A1 (ru) 2003-02-27
IS6551A (is) 2002-09-17
PT1272470E (pt) 2004-05-31
US6767917B1 (en) 2004-07-27
AR023788A1 (es) 2002-09-04
EP1272470A1 (de) 2003-01-08
GEP20043300B (en) 2004-02-10
HRP20000162B1 (en) 2004-06-30
ZA200208309B (en) 2003-10-15
CA2401908A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
ATE411332T1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
ID30590A (id) Celana sekali pakai jenis-celana pendek
ID30187A (id) Dongkrak jenis pantagraf
DE60114153D1 (de) Substituierte arylpyrazine
AR028393A1 (es) Iminoazidas substituidas
DE60125415D1 (de) Formeinsatz
DE60126814D1 (de) Inhalation von stickoxid
NO20030917L (no) Anvendelse
DE60127311D1 (de) Verbesserung von luftbleichkatalysatoren
NO20030276L (no) Fremgangsmåte
DE60107074D1 (de) Kristallin form ii von cabergolin
DE60117938D1 (de) Vorspannen von Bauteilen
AR028302A1 (es) Feniluracilos substituidos
ATE365721T1 (de) Substituierte benzoylcyclohexenone
DE60007360T2 (de) Amorphe modifikation von torasemid
DE50113112D1 (de) Schaltungsanordnung
DE60031450D1 (de) Polymorph v von torasemid
DE50115426D1 (de) Schaltungsanordnung
DE60021925D1 (de) Flash-spinnen von polycyclopenten
UA4579S (uk) Дозиметр-радіометр гамма-бета-випромінювань
FR2810531B1 (fr) Trocart de coelio-chirurgie
ATE326465T1 (de) Racematspaltung von trans 7-
FIU20000376U0 (fi) Laituri
FIU20000366U0 (fi) Laituri
UA4194S (uk) Комплект етикеток

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee